Lurbinectedin plus pembrolizumab in relapsed small cell lung cancer (SCLC): the phase I/II LUPER study. Calles A, Navarro A, Doger Speville Uribe BG, Alvarez Colome E, et al. J Thorac Oncol 2025 Feb 10:S1556-0864(25)00064.

Read + Share

Amedeo Smart

Independent Medical Education

Calles A, Navarro A, Doger Speville Uribe BG, Alvarez Colome E, et al. Lurbinectedin plus pembrolizumab in relapsed small cell lung cancer (SCLC): the phase I/II LUPER study. J Thorac Oncol 2025 Feb 10:S1556-0864(25)00064.
PMID: 39938593